VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

Q: What does CUSIP 92941V308 represent in this 13F holders report?

CUSIP 92941V308 is the security identifier for VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share in Q1 2026?

13 institutional investors reported VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 92941V308

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 18,514,484
Total 13F shares: 3,258,263
Share change: +1,701,762
Total reported value: $1,946,211
Price per share: $0.60
Number of holders: 13
Value change: +$1,017,842
Number of buys: 3
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 92941V308?
CUSIP 92941V308 identifies VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 92941V308:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PERCEPTIVE ADVISORS LLC	3/4/5	10%+ Owner	— class O/S missing	4,935,057	$11,251,930	—	16 Aug 2021	3/4/5
AI Biotechnology LLC	3/4/5	10%+ Owner	— class O/S missing	1,116,585	$2,545,814	—	01 Nov 2023	3/4/5
Shay Capital LLC	13F	Company	8.8%	1,624,349	$942,285	—	31 Dec 2025	13F
Anson Funds Management LP	13F	Company	6.9%	1,274,386	$739,271	—	31 Dec 2025	13F
Nantahala Capital Management, LLC	13F	Company	5.4%	1,000,000	$580,100	—	31 Dec 2025	13F
T3 Companies, LLC	13F	Company	5.1%	945,000	$548,195	—	31 Dec 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	3.4%	638,492	$370,000	—	31 Dec 2025	13F
KVP Capital Advisors, LP	13F	Company	2.7%	500,551	$290,370	—	31 Dec 2025	13F
Andrew Saik	3/4/5	Chief Financial Officer	— class O/S missing	116,468	$265,547	—	28 May 2021	3/4/5
Matthew T. Wiley	3/4/5	Chief Commercial Officer	— class O/S missing	109,246	$249,081	—	30 Jun 2021	3/4/5
David Domzalski	3/4/5	PRESIDENT AND CEO, Director	— mixed-class rows	1,131,976 mixed-class rows	$233,186	—	31 Mar 2026	3/4/5
VANGUARD GROUP INC	13F	Company	1.7%	314,545	$182,436	—	31 Dec 2025	13F
Ikarian Capital, LLC	13F	Company	1.4%	264,912	$153,675	—	31 Dec 2025	13F
Patrick G. Lepore	3/4/5	Director	— mixed-class rows	71,472 mixed-class rows	$150,298	—	12 Dec 2025	3/4/5
ADAR1 Capital Management, LLC	13F	Company	1.4%	253,791	$147,224	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.2%	225,152	$130,614	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	1.2%	220,000	$127,622	—	31 Dec 2025	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.88%	163,100	$94,614	—	31 Dec 2025	13F
Mutya Harsch	3/4/5	CHIEF LEGAL OFFICER AND GC	— mixed-class rows	351,898 mixed-class rows	$70,713	—	31 Mar 2026	3/4/5
Iain Stuart	3/4/5	CHIEF SCIENTIFIC OFFICER	— mixed-class rows	342,363 mixed-class rows	$65,181	—	31 Mar 2026	3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.54%	100,341	$58,207	—	31 Dec 2025	13F
Rangeley Capital, LLC	13F	Company	0.54%	100,000	$58,010	—	31 Dec 2025	13F
Tyler Zeronda	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	329,788 mixed-class rows	$57,887	—	31 Mar 2026	3/4/5
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.44%	81,371	$47,203	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.43%	79,040	$45,851	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.39%	72,356	$41,974	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.34%	62,761	$36,401	—	31 Dec 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.29%	53,961	$31,000	—	31 Dec 2025	13F
STALEY CAPITAL ADVISERS INC	13F	Company	— class O/S missing	51,472	$29,859	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.24%	44,405	$25,760	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F 13D/G	Company · Kenneth Griffin	0.02% from 13D/G	30,526	$17,708	—	31 Dec 2025	13F 13D/G
Virtu Financial LLC	13F	Company	0.14%	25,327	$15,000	—	31 Dec 2025	13F
FNY Investment Advisers, LLC	13F	Company	0.14%	25,000	$14,000	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.12%	23,110	$13,406	—	31 Dec 2025	13F
COMMONWEALTH EQUITY SERVICES, LLC	13F	Company	0.1%	18,298	$10,610	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.09%	15,765	$9,145	—	31 Dec 2025	13F
Harvest Investment Services, LLC	13F	Company	0.06%	11,059	$6,415	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.02%	3,567	$2,069	—	31 Dec 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.01%	2,440	$1,000	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	1,677	$973	—	31 Dec 2025	13F
ACORN CAPITAL ADVISORS, LLC	13F	Company	0.01%	1,425	$827	—	31 Dec 2025	13F
MB, LEVIS & ASSOCIATES, LLC	13F	Company	0.01%	1,041	$604	—	31 Dec 2025	13F
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	13F	Company	0%	800	$464	—	31 Dec 2025	13F
Hurley Capital, LLC	13F	Company	0%	561	$325	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	146	$85	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	65	$38	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0%	43	$25	—	31 Dec 2025	13F
Truvestments Capital LLC	13F	Company	0%	25	$15	—	31 Dec 2025	13F
Farther Finance Advisors, LLC	13F	Company	— class O/S missing	16	$9	—	31 Dec 2025	13F
Newbridge Financial Services Group, Inc.	13F	Company	0%	10	$6	—	31 Dec 2025	13F

Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) as of Q1 2026

As of 31 Mar 2026, VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) was held by 13 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,258,263 shares. The largest 10 holders included Lynx1 Capital Management LP, T3 Companies, LLC, VANGUARD CAPITAL MANAGEMENT LLC, VANGUARD FIDUCIARY TRUST CO, UBS Group AG, JANE STREET GROUP, LLC, FNY Investment Advisers, LLC, COMMONWEALTH EQUITY SERVICES, LLC, MB, LEVIS & ASSOCIATES, LLC, and Vanguard Global Advisers, LLC. This page lists 14 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-26

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.